B
Bullisch
Bullisch · 25%NAMS
$42.47
Szenariopreis
$20.010
-0.178 (-0.89%)Zum Schluss
Loading chart…
- Hoch
- 20.750
- Eröffnung
- 20.080
- Volumengewichteter Durchschnittskurs
- 20.11
- Volumen
- 2.19M
- Marktkap.
- 1.76B
- Tief
- 19.580
- Umsatz
- 44.07M
- EV/EBITDA, TTM
- -0.91
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
KI-Analyse of NewAmsterdam Pharma Company NV (NAMS)
VerkaufenNewAmsterdam Pharma is not a good buy right now due to significant financial losses and negative sentiment. The current price is $21.575, and the company reported a net loss of $64.1 million in Q2, which is a major concern. Additionally, the RSI is at 31.077, indicating that the stock is oversold but may not recover soon due to ongoing financial struggles.
Bewertungskennzahlen
Das aktuelle erwartete KGV von NewAmsterdam Pharma Company NV (NAMS) beträgt 119.05, verglichen mit dem 5-Jahres-Durchschnitt von 4.92.
Alphio-AI-Kursszenarien für NAMS
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die NAMS halten
Event-Zeitleiste
News
9.009-23PRnewswireMenarini and NewAmsterdam Receive EU Approval for New Drugs
8.509-22PRnewswireObicetrapib Receives First EU Market Approval for LDL-C Treatment
8.509-21PRnewswireObicetrapib Receives First-in-Class Approval
8.509-21PRnewswireNewAmsterdam and Menarini Achieve First Global Approval for Obicetrapib
8.509-21NewsfilterNewAmsterdam and Menarini Achieve First Global Approval for Obicetrapib
NAMS FAQ – beantwortet von Alphio AI
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
NewAmsterdam Pharma is not a good buy right now due to significant financial losses and negative sentiment. The current price is $21.575, and the company reported a net loss of $64.1 million in Q2, which is a major concern. Additionally, the RSI is at 31.077, indicating that the stock is oversold but may not recover soon due to ongoing financial struggles.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.